A Study of MHB042C in Patients With Advanced Solid Tumors

Summary

This is a first-in-human, open-label, multicenter Phase I/II study of MHB042C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB042C monotherapy.

Timeline

Start

2025-11-27

Primary completion

2029-10

Completion

2029-10

Drugs

Indications